The FDA approved Hikma's first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic ...

The dawn of 2025 marks a turning point for the packaging industry in the UK, with the introduction of the Extended Producer Responsibility (EPR) regulations. / Credit: cybrain via GettyImages As we ...

Liraglutide (Victoza) is a potent anti-diabetic agent. It is the first and only human GLP-1 analog drug, synthesized by recombinant DNA expression in the species saccharomyces cerevisiae and has been ...

The U.S. Food and Drug Administration (FDA) granted approval on the 23rd (local time) for the generic product of Victoza (ingredient: liraglutide), a treatment for type 2 diabetes in patients aged ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to ...

Companies adopt new materials, minimalist designs, and AI for eco-friendly packaging. / Credit: Pedal to the Stock via Shutterstock As the packaging industry approaches 2025, several key trends are ...

THURSDAY, Dec. 26, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 ...

Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic. The FDA supports the development of generic drugs, such as GLP-1s, by ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist ...